Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis : A Single-Group, Open-Label, Phase 2b, Multicenter Study

By afschroeder • July 21, 2026

Donovan FM, Johnson RH, Patterson TF, Hoenigl M, Spec A, Sikka MK, Holland SM, Shoham S, Schaenman JM, Mehta SR, Kuran RA, Galgiani JN, Bresnik M, Rex JH, Thompson GR 3rd. Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis : A Single-Group, Open-Label, Phase 2b, Multicenter Study. Ann Intern Med. 2026 Jul 21. doi: 10.7326/ANNALS-26-00103. Epub ahead of print. PMID: 42475691.

Tags: Infectious Diseases, Kern, Publications

The transcription factor Ahr1 governs the recruitment of neutrophils to the brain and clearance of Candida albicans during CNS infection

Wakade RS, Solis NV, Ristow LC, Wellington M, Filler SG, Krysan DJ. The transcription factor Ahr1 governs the recruitment of neutrophils to the brain and[...]

The hantavirus question we are not asking

Hensley LE, Halbrook M, Hoff NA, Merritt S, Olinger GG, Skinner B, von Fricken ME, Kindrachuk J, Rimoin AW. The hantavirus question we are not[...]

Advanced HIV Disease at First Diagnosis in South Brazil Extended Beyond Traditionally Targeted Populations: A 10-Year Hospital-Based Study (2015-2024)

Hernandez CJ, Fonseca PM, Noal A, Zywica M, Cambou MC, Varella IRDS, Santos BR, de Melo MG, Nielsen-Saines K. Advanced HIV Disease at First Diagnosis[...]